Endothelial cell-based systemic gene therapy of metastatic melanoma
1Department of Oncology, Georgetown University Medical Center, N.W. Washington, DC 20007, USA.
Abstract:
Cancer metastasis accounts for a significant proportion of morbidity and mortality in patients. Effective means of treating disseminated disease remains elusive. The purpose of this study was to determine whether genetically modified endothelial cells (GMEC) can selectively target and deliver recombinant therapeutic molecules to sites of tumor metastases. Following the establishment of lung metastases of 4T1 mammary tumor in mice, intravenously (i.v.) administered, lacZ transgene-expressing endothelial cells (lacZ-GMEC) accumulated at the tumor sites. An average of 32% and 90% of the pulmonary metastases were X-gal stained following one and three tail vein injections of 10(5) lacZ-GMEC, respectively. The linear pattern of X-gal staining seen within the tumor sites and the histological appearance of the tumor vasculature were consistent with the incorporation of lacZ-GMEC into blood vessels. In C57Bl/6 mice harboring lung metastases of melanoma, the administration of three sequential i.v. injections of 10(5) endothelial cells expressing a human interleukin 2 transgene abrogated the tumor metastases and prolonged survival of the animals. These results demonstrate that i.v.-administered GMEC can selectively accumulate, survive, and stably express exogenous genes at multiple tumor sites. These findings support a role for i.v.-administered GMEC as a potential therapeutic strategy for the systemic treatment of cancer metastases.
Insights
Genetically modified endothelial cells (GMEC) can target cancer metastases. These cells accumulate at tumor sites and deliver therapeutic molecules, offering a potential systemic treatment for disseminated cancer.
Area of Science:
- Oncology
- Vascular Biology
- Gene Therapy
Background:
- Cancer metastasis is a primary cause of cancer-related death.
- Current treatments for disseminated cancer are limited.
- Targeted delivery of therapeutics to metastatic sites is crucial.
Purpose of the Study:
- To investigate the potential of genetically modified endothelial cells (GMEC) for targeting and treating cancer metastases.
- To determine if GMEC can selectively accumulate at tumor sites and deliver therapeutic payloads.
Main Methods:
- Establishment of lung metastases in mouse models (4T1 mammary tumor and melanoma).
- Intravenous (i.v.) administration of lacZ transgene-expressing endothelial cells (lacZ-GMEC) and interleukin 2-expressing endothelial cells.
- Assessment of GMEC accumulation and gene expression at tumor sites using X-gal staining and histological analysis.
- Evaluation of therapeutic efficacy by measuring tumor burden and animal survival.
Main Results:
- Administered lacZ-GMEC selectively accumulated in lung metastases, with significant X-gal staining observed after injections.
- Histological analysis confirmed the incorporation of lacZ-GMEC into the tumor vasculature.
- Sequential i.v. injections of interleukin 2-expressing GMEC abrogated melanoma lung metastases and prolonged survival in mice.
- GMEC demonstrated selective accumulation, survival, and stable expression of exogenous genes at multiple tumor sites.
Conclusions:
- Intravenously administered GMEC can effectively target and accumulate at sites of cancer metastasis.
- GMEC can serve as a delivery vehicle for therapeutic molecules, potentially treating disseminated cancer.
- GMEC-based therapy represents a promising strategy for the systemic treatment of metastatic disease.
Related Concept Videos
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy